Skip to content

Teleflex TFX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Medtronic logo
MedtronicMDT
$20.93B+0.4%
Solventum logo
SolventumSOLV
$3.9B+3.0%
Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%
Novanta logo
NovantaNOVT
$556.41M+609%
Penumbra logo
PenumbraPEN
$1.2B+7.6%
Globus Medical logo
Globus MedicalGMED
$3.21B+5.0%

Other financials

Income statement

See full
Revenue$548.3M+32.3%
Gross profit$307.4M+20.4%
Operating income$20.2M-73.4%
Net income-$8.2M-109%
EPS (diluted)-$0.18-109%

Balance sheet

See full
Cash & equivalents$329.6M+16.8%
Total debt$2.8B+38.6%
Total equity$3.1B-24.7%
Total assets$6.8B-5.3%

Cash flow

See full
Operating cash flow$46.7M+68.3%
CapEx$18.8M-22.1%
Free cash flow$27.9M+676%

Valuation

See full
Market cap$5.62B-14.4%
Enterprise value$8.07B-2.0%
P/S2.6×-1.2×

Profitability

See full
Gross margin38.2%-3.0pp
Operating margin3%-11.8pp
Net margin-47.4%-56.2pp
FCF margin7.9%

Returns & leverage

See full
Return on equity-28.1%-31.6pp
Debt / equity0.9×+0.4×
Current ratio2.6×+0.3×

Where this comes from

Reported directly by Teleflex in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Teleflex’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Teleflex's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Teleflex's additional paid-in capital?
Teleflex (TFX) reported additional paid-in capital of $815.81M in Q4 2025.
How has Teleflex's additional paid-in capital changed year-over-year?
Teleflex's additional paid-in capital increased by 4.4% year-over-year, from $781.18M to $815.81M.
What is the long-term trend for Teleflex's additional paid-in capital?
Over 5 years (2020 to 2025), Teleflex's additional paid-in capital has grown at a 4.6% compound annual growth rate (CAGR), from $652.31M to $815.81M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.